APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Drugs for Intestinal Diseases

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide Drugs for Intestinal Diseases Market Outlook and Growth Opportunities 2026

23 December 2025198 pages

Choose your research edition.

Industry ResearchPeptide Drugs for Intestinal Diseases Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Drugs for Intestinal Diseases Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Peptide Drugs for Intestinal Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Drugs for Intestinal Diseases Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Drugs for Intestinal Diseases Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Peptide Drugs for Intestinal Diseases market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide Drugs for Intestinal Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide Drugs for Intestinal Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Drugs for Intestinal Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide Drugs for Intestinal Diseases market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide Drugs for Intestinal Diseases market include Takeda Pharmaceuticals, AbbVie and Salix Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide Drugs for Intestinal Diseases market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Drugs for Intestinal Diseases and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Drugs for Intestinal Diseases sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide Drugs for Intestinal Diseases market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide Drugs for Intestinal Diseases Segment by Company

Takeda Pharmaceuticals

AbbVie

Salix Pharmaceuticals

Peptide Drugs for Intestinal Diseases Segment by Type

Teduglutide

Plecanatide

Linaclotide

Peptide Drugs for Intestinal Diseases Segment by Application

Hospital

Clinic

Others

Peptide Drugs for Intestinal Diseases Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide Drugs for Intestinal Diseases status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peptide Drugs for Intestinal Diseases market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide Drugs for Intestinal Diseases significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide Drugs for Intestinal Diseases competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Drugs for Intestinal Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Drugs for Intestinal Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Drugs for Intestinal Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Drugs for Intestinal Diseases market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Drugs for Intestinal Diseases industry.

Chapter 3: Detailed analysis of Peptide Drugs for Intestinal Diseases manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peptide Drugs for Intestinal Diseases in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peptide Drugs for Intestinal Diseases in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide Drugs for Intestinal Diseases Industry Trends Table 2. Peptide Drugs for Intestinal Diseases Industry Drivers Table 3. Peptide Drugs for Intestinal Diseases Industry Opportunities and Challenges Table 4. Peptide Drugs for Intestinal Diseases Industry Restraints Table 5. Global Peptide Drugs for Intestinal Diseases Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide Drugs for Intestinal Diseases Revenue Share by Company (2021-2026) Table 7. Global Peptide Drugs for Intestinal Diseases Sales Volume by Company (kg) & (2021-2026) Table 8. Global Peptide Drugs for Intestinal Diseases Sales Volume Share by Company (2021-2026) Table 9. Global Peptide Drugs for Intestinal Diseases Average Price (USD/g) of Company (2021-2026) Table 10. Global Peptide Drugs for Intestinal Diseases Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peptide Drugs for Intestinal Diseases Key Company Manufacturing Base & Headquarters Table 12. Global Peptide Drugs for Intestinal Diseases Company, Product Type & Application Table 13. Global Peptide Drugs for Intestinal Diseases Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide Drugs for Intestinal Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Teduglutide Table 18. Significant Companies of Plecanatide Table 19. Significant Companies of Linaclotide Table 20. Global Peptide Drugs for Intestinal Diseases Sales Volume by Type 2021 VS 2025 VS 2032 (kg) Table 21. Global Peptide Drugs for Intestinal Diseases Sales Volume by Type (2021-2026) & (kg) Table 22. Global Peptide Drugs for Intestinal Diseases Sales Volume by Type (2027-2032) & (kg) Table 23. Global Peptide Drugs for Intestinal Diseases Sales Volume Share by Type (2021-2026) Table 24. Global Peptide Drugs for Intestinal Diseases Sales Volume Share by Type (2027-2032) Table 25. Global Peptide Drugs for Intestinal Diseases Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Peptide Drugs for Intestinal Diseases Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Peptide Drugs for Intestinal Diseases Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Peptide Drugs for Intestinal Diseases Sales Value Share by Type (2021-2026) Table 29. Global Peptide Drugs for Intestinal Diseases Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Others Table 33. Global Peptide Drugs for Intestinal Diseases Sales Volume by Application 2021 VS 2025 VS 2032 (kg) Table 34. Global Peptide Drugs for Intestinal Diseases Sales Volume by Application (2021-2026) & (kg) Table 35. Global Peptide Drugs for Intestinal Diseases Sales Volume by Application (2027-2032) & (kg) Table 36. Global Peptide Drugs for Intestinal Diseases Sales Volume Share by Application (2021-2026) Table 37. Global Peptide Drugs for Intestinal Diseases Sales Volume Share by Application (2027-2032) Table 38. Global Peptide Drugs for Intestinal Diseases Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Peptide Drugs for Intestinal Diseases Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Peptide Drugs for Intestinal Diseases Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Peptide Drugs for Intestinal Diseases Sales Value Share by Application (2021-2026) Table 42. Global Peptide Drugs for Intestinal Diseases Sales Value Share by Application (2027-2032) Table 43. Global Peptide Drugs for Intestinal Diseases Sales by Region: 2021 VS 2025 VS 2032 (kg) Table 44. Global Peptide Drugs for Intestinal Diseases Sales by Region (2021-2026) & (kg) Table 45. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Region (2021-2026) Table 46. Global Peptide Drugs for Intestinal Diseases Sales by Region (2027-2032) & (kg) Table 47. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Region (2027-2032) Table 48. Global Peptide Drugs for Intestinal Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Peptide Drugs for Intestinal Diseases Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Peptide Drugs for Intestinal Diseases Sales Value Share by Region (2021-2026) Table 51. Global Peptide Drugs for Intestinal Diseases Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Peptide Drugs for Intestinal Diseases Sales Value Share by Region (2027-2032) Table 53. Global Peptide Drugs for Intestinal Diseases Market Average Price (USD/g) by Region (2021-2026) Table 54. Global Peptide Drugs for Intestinal Diseases Market Average Price (USD/g) by Region (2027-2032) Table 55. Global Peptide Drugs for Intestinal Diseases Sales by Country: 2021 VS 2025 VS 2032 (kg) Table 56. Global Peptide Drugs for Intestinal Diseases Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Peptide Drugs for Intestinal Diseases Sales by Country (2021-2026) & (kg) Table 58. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Country (2021-2026) Table 59. Global Peptide Drugs for Intestinal Diseases Sales by Country (2027-2032) & (kg) Table 60. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Country (2027-2032) Table 61. Global Peptide Drugs for Intestinal Diseases Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Peptide Drugs for Intestinal Diseases Sales Value Market Share by Country (2021-2026) Table 63. Global Peptide Drugs for Intestinal Diseases Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Peptide Drugs for Intestinal Diseases Sales Value Market Share by Country (2027-2032) Table 65. Takeda Pharmaceuticals Company Information Table 66. Takeda Pharmaceuticals Business Overview Table 67. Takeda Pharmaceuticals Peptide Drugs for Intestinal Diseases Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 68. Takeda Pharmaceuticals Peptide Drugs for Intestinal Diseases Product Portfolio Table 69. Takeda Pharmaceuticals Recent Development Table 70. AbbVie Company Information Table 71. AbbVie Business Overview Table 72. AbbVie Peptide Drugs for Intestinal Diseases Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 73. AbbVie Peptide Drugs for Intestinal Diseases Product Portfolio Table 74. AbbVie Recent Development Table 75. Salix Pharmaceuticals Company Information Table 76. Salix Pharmaceuticals Business Overview Table 77. Salix Pharmaceuticals Peptide Drugs for Intestinal Diseases Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 78. Salix Pharmaceuticals Peptide Drugs for Intestinal Diseases Product Portfolio Table 79. Salix Pharmaceuticals Recent Development Table 80. Key Raw Materials Table 81. Raw Materials Key Suppliers Table 82. Peptide Drugs for Intestinal Diseases Distributors List Table 83. Peptide Drugs for Intestinal Diseases Customers List Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Peptide Drugs for Intestinal Diseases Product Image Figure 2. Global Peptide Drugs for Intestinal Diseases Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Drugs for Intestinal Diseases Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peptide Drugs for Intestinal Diseases Sales (2021-2032) & (kg) Figure 5. Global Peptide Drugs for Intestinal Diseases Sales Average Price (USD/g) & (2021-2032) Figure 6. Global Peptide Drugs for Intestinal Diseases Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Teduglutide Image Figure 10. Plecanatide Image Figure 11. Linaclotide Image Figure 12. Global Peptide Drugs for Intestinal Diseases Sales Volume by Type (2021 VS 2025 VS 2032) & (kg) Figure 13. Global Peptide Drugs for Intestinal Diseases Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Peptide Drugs for Intestinal Diseases Sales Volume Share by Type (2021-2032) Figure 15. Global Peptide Drugs for Intestinal Diseases Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Peptide Drugs for Intestinal Diseases Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Peptide Drugs for Intestinal Diseases Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Peptide Drugs for Intestinal Diseases Sales Volume by Application (2021 VS 2025 VS 2032) & (kg) Figure 22. Global Peptide Drugs for Intestinal Diseases Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Peptide Drugs for Intestinal Diseases Sales Volume Share by Application (2021-2032) Figure 24. Global Peptide Drugs for Intestinal Diseases Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Peptide Drugs for Intestinal Diseases Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Peptide Drugs for Intestinal Diseases Sales Value Share by Application (2021-2032) Figure 27. Global Peptide Drugs for Intestinal Diseases Sales by Region: 2021 VS 2025 VS 2032 (kg) Figure 28. Global Peptide Drugs for Intestinal Diseases Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Peptide Drugs for Intestinal Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Peptide Drugs for Intestinal Diseases Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Peptide Drugs for Intestinal Diseases Sales Value (2021-2032) & (US$ Million) Figure 32. North America Peptide Drugs for Intestinal Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Peptide Drugs for Intestinal Diseases Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Peptide Drugs for Intestinal Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Peptide Drugs for Intestinal Diseases Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Peptide Drugs for Intestinal Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Peptide Drugs for Intestinal Diseases Sales Value (2021-2032) & (US$ Million) Figure 38. South America Peptide Drugs for Intestinal Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Peptide Drugs for Intestinal Diseases Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Peptide Drugs for Intestinal Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Peptide Drugs for Intestinal Diseases Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Peptide Drugs for Intestinal Diseases Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Teduglutide
  • Plecanatide
  • Linaclotide
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • AbbVie
  • Salix Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide Drugs for Intestinal Diseases Sales Value (2021-2032)
  4. 1.2.2 Global Peptide Drugs for Intestinal Diseases Sales Volume (2021-2032)
  5. 1.2.3 Global Peptide Drugs for Intestinal Diseases Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peptide Drugs for Intestinal Diseases Market Dynamics
  1. 2.1 Peptide Drugs for Intestinal Diseases Industry Trends
  2. 2.2 Peptide Drugs for Intestinal Diseases Industry Drivers
  3. 2.3 Peptide Drugs for Intestinal Diseases Industry Opportunities and Challenges
  4. 2.4 Peptide Drugs for Intestinal Diseases Industry Restraints
3 Peptide Drugs for Intestinal Diseases Market by Company
  1. 3.1 Global Peptide Drugs for Intestinal Diseases Company Revenue Ranking in 2025
  2. 3.2 Global Peptide Drugs for Intestinal Diseases Revenue by Company (2021-2026)
  3. 3.3 Global Peptide Drugs for Intestinal Diseases Sales Volume by Company (2021-2026)
  4. 3.4 Global Peptide Drugs for Intestinal Diseases Average Price by Company (2021-2026)
  5. 3.5 Global Peptide Drugs for Intestinal Diseases Company Ranking (2024-2026)
  6. 3.6 Global Peptide Drugs for Intestinal Diseases Company Manufacturing Base and Headquarters
  7. 3.7 Global Peptide Drugs for Intestinal Diseases Company Product Type and Application
  8. 3.8 Global Peptide Drugs for Intestinal Diseases Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peptide Drugs for Intestinal Diseases Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peptide Drugs for Intestinal Diseases Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peptide Drugs for Intestinal Diseases Market by Type
  1. 4.1 Peptide Drugs for Intestinal Diseases Type Introduction
  2. 4.1.1 Teduglutide
  3. 4.1.2 Plecanatide
  4. 4.1.3 Linaclotide
  5. 4.2 Global Peptide Drugs for Intestinal Diseases Sales Volume by Type
  6. 4.2.1 Global Peptide Drugs for Intestinal Diseases Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Peptide Drugs for Intestinal Diseases Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Peptide Drugs for Intestinal Diseases Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Peptide Drugs for Intestinal Diseases Sales Value by Type
  10. 4.3.1 Global Peptide Drugs for Intestinal Diseases Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Peptide Drugs for Intestinal Diseases Sales Value by Type (2021-2032)
  12. 4.3.3 Global Peptide Drugs for Intestinal Diseases Sales Value Share by Type (2021-2032)
5 Peptide Drugs for Intestinal Diseases Market by Application
  1. 5.1 Peptide Drugs for Intestinal Diseases Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Peptide Drugs for Intestinal Diseases Sales Volume by Application
  6. 5.2.1 Global Peptide Drugs for Intestinal Diseases Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide Drugs for Intestinal Diseases Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Peptide Drugs for Intestinal Diseases Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Peptide Drugs for Intestinal Diseases Sales Value by Application
  10. 5.3.1 Global Peptide Drugs for Intestinal Diseases Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peptide Drugs for Intestinal Diseases Sales Value by Application (2021-2032)
  12. 5.3.3 Global Peptide Drugs for Intestinal Diseases Sales Value Share by Application (2021-2032)
6 Peptide Drugs for Intestinal Diseases Regional Sales and Value Analysis
  1. 6.1 Global Peptide Drugs for Intestinal Diseases Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Drugs for Intestinal Diseases Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide Drugs for Intestinal Diseases Sales by Region: 2021-2026
  4. 6.2.2 Global Peptide Drugs for Intestinal Diseases Sales by Region (2027-2032)
  5. 6.3 Global Peptide Drugs for Intestinal Diseases Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peptide Drugs for Intestinal Diseases Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peptide Drugs for Intestinal Diseases Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peptide Drugs for Intestinal Diseases Sales Value by Region (2027-2032)
  9. 6.5 Global Peptide Drugs for Intestinal Diseases Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peptide Drugs for Intestinal Diseases Sales Value (2021-2032)
  12. 6.6.2 North America Peptide Drugs for Intestinal Diseases Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peptide Drugs for Intestinal Diseases Sales Value (2021-2032)
  15. 6.7.2 Europe Peptide Drugs for Intestinal Diseases Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peptide Drugs for Intestinal Diseases Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peptide Drugs for Intestinal Diseases Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peptide Drugs for Intestinal Diseases Sales Value (2021-2032)
  21. 6.9.2 South America Peptide Drugs for Intestinal Diseases Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peptide Drugs for Intestinal Diseases Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peptide Drugs for Intestinal Diseases Sales Value Share by Country, 2025 VS 2032
7 Peptide Drugs for Intestinal Diseases Country-level Sales and Value Analysis
  1. 7.1 Global Peptide Drugs for Intestinal Diseases Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide Drugs for Intestinal Diseases Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peptide Drugs for Intestinal Diseases Sales by Country (2021-2032)
  4. 7.3.1 Global Peptide Drugs for Intestinal Diseases Sales by Country (2021-2026)
  5. 7.3.2 Global Peptide Drugs for Intestinal Diseases Sales by Country (2027-2032)
  6. 7.4 Global Peptide Drugs for Intestinal Diseases Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peptide Drugs for Intestinal Diseases Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peptide Drugs for Intestinal Diseases Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peptide Drugs for Intestinal Diseases Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peptide Drugs for Intestinal Diseases Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peptide Drugs for Intestinal Diseases Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Peptide Drugs for Intestinal Diseases Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Peptide Drugs for Intestinal Diseases Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 AbbVie
  8. 8.2.1 AbbVie Company Information
  9. 8.2.2 AbbVie Business Overview
  10. 8.2.3 AbbVie Peptide Drugs for Intestinal Diseases Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Peptide Drugs for Intestinal Diseases Product Portfolio
  12. 8.2.5 AbbVie Recent Developments
  13. 8.3 Salix Pharmaceuticals
  14. 8.3.1 Salix Pharmaceuticals Company Information
  15. 8.3.2 Salix Pharmaceuticals Business Overview
  16. 8.3.3 Salix Pharmaceuticals Peptide Drugs for Intestinal Diseases Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Salix Pharmaceuticals Peptide Drugs for Intestinal Diseases Product Portfolio
  18. 8.3.5 Salix Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide Drugs for Intestinal Diseases Value Chain Analysis
  2. 9.1.1 Peptide Drugs for Intestinal Diseases Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide Drugs for Intestinal Diseases Sales Mode & Process
  6. 9.2 Peptide Drugs for Intestinal Diseases Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide Drugs for Intestinal Diseases Distributors
  9. 9.2.3 Peptide Drugs for Intestinal Diseases Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst